The DOI matches its Crossref record.
A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
Open accessAbstract
Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero®, Novartis Vaccines and Diagnostics), contains three surface-exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ OMV) with PorA 1.4 antigenicity. This comprehensive review of the 4CMenB clinical development program covers pivotal phase I/IIb/III studies in over 7,000 adults, adolescents, and infants. The immunological correlate for clinical protection used was human complement-mediated serum bactericidal activity titers ≥4 or 5 against indicator strains for individual antigens. Based on achievement of protective titers, a four-dose schedule (three primary doses and one booster dose) for infants and a two-dose schedule for adolescents provided the best results. Observed increases in injection site pain/tenderness and fever in infants, and injection site pain, malaise, and headache in adolescents compared with routine vaccines, were mostly mild to moderate; frequencies of rare events (Kawasaki disease, juvenile arthritis) were not significantly different from non-vaccinated individuals. 4CMenB is conservatively estimated to provide 66-91 % coverage against meningococcal serogroup B strains worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 435
Outer membrane vesicles as platform vaccine technology
van der Pol, L., Stork, M., & van der Ley, P. (2015) · Biotechnology Journal · doi:10.1002/biot.201400395 · Cited by 378
Martin, N. G., Sadarangani, M., Pollard, A. J., & Goldacre, M. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70027-1 · Cited by 131
The Genetics of Neisseria Species
Rotman, E., & Seifert, H. S. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092007 · Cited by 122
Emerging experience with meningococcal serogroup B protein vaccines
Toneatto, D., Pizza, M., Masignani, V., & Rappuoli, R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1308828 · Cited by 67
Self-citation
Metadata
- Authors
- O’Ryan, M., Stoddard, J., Toneatto, D., Wassil, J., & Dull, P. M.
- Venue
- Drugs
- Published
- 2013-12-12
- Volume
- 74
- Issue
- 1
- Pages
- 15-30
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2072220396
- Cited by
- 172
- References
- 0
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. https://app.cochat.ai/papers/10.1007/s40265-013-0155-7
- The paper
- O’Ryan, M., Stoddard, J., Toneatto, D., Wassil, J., & Dull, P. M. (2014). A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. Drugs. https://doi.org/10.1007/s40265-013-0155-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.